SBIR/STTR Research Award

Targeting Exonuclease Resistant RNA to Develop Zika Virus Therapeutics

Award identifier ff7638285ac7a7e3a6e9069ad0040b12d8b6a94b58020469cc06cf0ea437fdceAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$299,236

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Nymirum, Inc.
Proposal award date
2018-01-01
Contract end date
2019-10-31
UEI
ZJRRLDJNHJC9
Solicitation number
PA16-302
Topic code
NIAID

Research abstract

Project Summary Abstract Outbreaks of Zika VirusZIKVhave been recorded in Africathe AmericasAsiaand the Pacificand despite significant resources being dedicated to combat ZIKV proliferationthere is no known cureMany mosquitoborne flavivirus such as ZIKVDengue virusYellow Fever virusand West Nile virus have structuredUTRsStructured RNA elements in theUTRs allow the virus to resist degradation by host exonucleases during infection leading to the production of noncoding subgenomic flavivirus RNAswhich are directly linked to cytopathic and pathologic effects by dysregulating RNA decay pathways and binding cellular proteins important for antiviral responseWe aim to develop small molecules that target the ZIKV exonuclease resistant RNA to promote ZIKV genome degradation by host exonucleases and inhibit viral proliferation and infectionSuccessfully demonstrating that flaviviral exonuclease resistant RNAs can be targeted by small molecules to inhibit viral proliferation and infection has the potential to create an entirely new field of anti flavivral drug discovery and lead to the development of broad spectrum anti flaviviral therapeutics Project Narrative Outbreaks of ZIKV have been recorded in Africathe AmericasAsiaand the Pacificand despite significant resources being dedicated to combat ZIKV proliferationthere is no known cureWe aim to develop small molecules that target the ZIKV exonuclease resistant RNA to promote ZIKV genome degradation by host exonucleases and inhibit viral proliferation and infectionSuccessfully demonstrating that flaviviral exonuclease resistant RNAs can be targeted by small molecules to inhibit viral proliferation and infection has the potential to create an entirely new field of anti flavivral drug discovery and lead to the development of broad spectrum anti flaviviral therapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2013–2020). Reported award amounts total $2,813,579. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.